Lv5
1090 积分 2022-10-26 加入
Exploring the next generation of antibody–drug conjugates
17天前
已完结
Unlocking biological barriers: nonclinical safety considerations for RNA-based complex biologics
18天前
已完结
Unlocking biological barriers: nonclinical safety considerations for RNA-based complex biologics
18天前
已完结
Systematic Evaluation of Maleimide Spacer Impact on Drug-Linker Deconjugation in Antibody-Drug Conjugates Ex Vivo and In Vivo
22天前
已完结
Unveiling the molecular and immunological drivers of antibody–drug conjugates in cancer treatment
1个月前
已完结
An Industry Perspective on Key Considerations for the ICH S13 Guidance: Nonclinical Safety Evaluations of Oligonucleotide-Based Therapeutics
1个月前
已完结
Targeting DNA damage response pathways in cancer
2个月前
已完结
First-line concomitant EGFR-TKI + chemotherapy versus EGFR-TKI alone for advanced EGFR -mutated NSCLC: a meta-analysis of randomized phase III trials
2个月前
已完结
New promises and challenges in the treatment of advanced non-small-cell lung cancer
2个月前
已完结
体内嵌合抗原受体T细胞（in vivo CAR-T）研究进展及非临床研究一般考虑
3个月前
已完结
皖公网安备34019202002308
